Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy

World Journal of Surgical Oncology

Jiren Yu¹  Qing Zhang¹  Xiaomei Huang¹  Hang Yu¹  Chao Chen¹  Xiaokun Liu¹  Xiaosun Liu¹  Geer Zhang¹  Hailong Jin¹ 

[1] Department of Gastrointestinal Surgery, the First Affiliated Hospital, Medical College, Zhejiang University, No. 79, Qingchun Road, Hangzhou, Zhejiang Province 310003, China

关键词: Prognosis;    Multivariate analysis;    Univariate analysis;    Neutrophil-lymphocyte ratio;    Gastric cancer;   

Others  :  1204415
DOI  :  10.1186/1477-7819-11-112

 received in 2012-11-02, accepted in 2013-05-09,  发布年份 2013

【 摘 要 】

Background

Accurate predictors of survival for patients with advanced gastric cancer treated with neoadjuvant chemotherapy are currently lacking. In this study, we aimed to evaluate the prognostic significance of the neutrophil-lymphocyte ratio (NLR) in patients with stage III-IV gastric cancer who received neoadjuvant chemotherapy.

Methods

We enrolled 46 patients in this study. The NLR was divided into two groups: high (>2.5) and low (≤2.5). Univariate analysis on progression-free survival (PFS) and overall survival(OS) was performed using the Kaplan-Meier and log-rank tests, and multivariate analysis was conducted using the Cox proportional hazards regression model. We analyzed whether chemotherapy normalized high NLR or not, and evaluated the prognostic significance of normalization on survival.

Results

The univariate analysis showed that PFS and OS were both worse for patients with high NLR than for those with low NLR before chemotherapy (median PFS 16 and 49 months, respectively, P = 0.012; median OS 21 and 52 months, P = 0.113). PFS and OS were also worse for patients with high NLR than for those with low NLR before surgery (median PFS 12 and 35 months, P = 0.019; median OS 21 and 52 months, P = 0.082). Multivariate analysis showed that both NLR before chemotherapy and surgery were independent prognostic factors of PFS. Neoadjuvant chemotherapy normalized high NLR in 11 of 24 patients, and these 11 patients had better median PFS and OS than the 13 patients who had high NLR both before chemotherapy and before surgery (PFS: 35.0 and 10.0 months, P = 0.003; OS: 60 and 16 months, P = 0.042).

Conclusions

NLR may serve as a potential biomarker for survival prognosis in patients with stage III-IV gastric cancer receiving neoadjuvant chemotherapy.

【 授权许可】

   
2013 Jin et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Canc J Clin 2011, 61:69-90.
• [2]Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ: MAGIC trial participants: perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med 2006, 355:11-20.
• [3]Li ZY, Shan F, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Wu Q, Ren H, Ji JF: Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol 2011, 9:110. BioMed Central Full Text
• [4]Würl P, Weigmann F, Meye A, Fittkau M, Rose U, Berger D, Rath FW, Dralle H, Taubert H: Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol 1997, 32:1147-1151.
• [5]Nakajima K, Ochiai T, Suzuki T, Shimada H, Hayashi H, Yasumoto A, Takeda A, Hishikawa E, Isono K: Impact of preoperative serum carcinoembryonic antigen, CA 19–9 and alpha fetoprotein levels in gastric cancer patients. Tumour Biol 1998, 19:464-469.
• [6]Bao GQ, Qiao Q, Zhao HD, He XL: Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol 2010, 8:52. BioMed Central Full Text
• [7]Shirai O, Ohmiya N, Taguchi A, Nakamura M, Kawashima H, Miyahara R, Itoh A, Hirooka Y, Watanabe O, Ando T, Goto Y, Hamajima N, Goto H: P53, P21 and P73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology 2010, 57:1595-1601.
• [8]Kim KH, Kwon HC, Oh SY, Kim SH, Lee S, Kwon KA, Jang JS, Kim MC, Kim SJ, Kim HJ: Clinicopathological significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-Fu and cisplatin chemotherapy. Biomarkers 2011, 16:74-82.
• [9]Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867.
• [10]Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001, 357:539-545.
• [11]Crumley AB, McMilan DC, Mckernan M, Going JJ, Shearer CJ, Stuart RC: An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Brit J Canc 2006, 94:1568-1571.
• [12]Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A: Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Canc Res 2008, 14:710-714.
• [13]Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 2009, 181:1004-1012.
• [14]Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Brit J Canc 2005, 93:273-278.
• [15]Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keiholz U: Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol 2007, 25:1562-1569.
• [16]Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Canc Res Clin Oncol 1998, 124:329-334.
• [17]Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007, 73:215-220.
• [18]Shimada H, Tajiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, Miyazaki A, Gunji H, Yamamoto H, Nagata M: High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Canc 2010, 13:170-176.
• [19]Aliustaoglu M, Bilici A, Ustaalioglu BB, Konya V, Gucun M, Seker M, Gumus M: The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment. Med Oncol 2010, 27:1060-1065.
• [20]Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY, Kim YJ: Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol 2011, 104:504-510.
• [21]Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91:181-184.
• [22]Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, Wan DS, Pan ZZ: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010, 25:1427-1433.
• [23]Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M: Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Canc 2009, 45:1950-1958.
• [24]Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC: Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg 2012, 204:294-299.
• [25]Kunisaki C, Takahashi M, Ono HA, Oshima T, Takagawa R, Kimura J, Kosaka T, Makino H, Akiyama H, Endo I: Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and S-1 combination chemotherapy. Oncology 2012, 83:183-191.
• [26]Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN: Blood neutrophil to lymphocyte ratio predicts survival in patients with colorectal live metastases treated with systemic chemotherapy. Ann Surg Oncol 2009, 16:614-622.
• [27]Chua W, Charles KA, Baracos VE, Clarke SJ: Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Brit J Canc 2011, 104:1288-1295.
• [28]Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RESIST guideline (version 1.1). Eur J Canc 2009, 45:228-247.
• [29]D’Ugo D, Rausei S, Biondi A, Persiani R: Preoperative treatment and surgery in gastric cancer :friends or foes? Lancet Oncol 2009, 10:191-195.
• [30]Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M: Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg 2010, 34:285-290.
• [31]Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Canc 2011, 47:2633-2641.
• [32]Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ: Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Canc 2011, 11:489. BioMed Central Full Text
• [33]Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY, Kim YR: Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 2012, 83:292-299.
• [34]Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE: Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine 1998, 10:254-257.
• [35]Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L: VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine 2005, 30:93-99.
• [36]Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP: Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 2007, 104:20262-20267.
• [37]EL-Hag A, Clark RA: Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol 1987, 139:2406-2413.
• [38]Shau H, Kim A: Suppression of lymphokine-activated killer induction by neutrophils. J Immunol 1988, 141:4395-4402.